Porcine urinary bladder matrix: A retrospective study and establishment of protocol

Journal of Wound Care

Volumn 21, Issue 10, 2012, Pages 476-482

  LeCheminant, J ^a   Field, C ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Advanced modality; Chronic wound; Debridement; Extracellular matrix; Offloading; Wound dressing

Indexed keywords

EID: 84867756138     PISSN: 09690700     EISSN: None     Source Type: Journal    
DOI: 10.12968/jowc.2012.21.10.476     Document Type: Review

References (16)

1. Rosario, D.J., Reilly, G.C., Ali Salah, E. et al. Decellularization and sterilization of porcine urinary bladder matrix for tissue engineering in the lower urinary tract. Regen Med. 2008; 3: 2, 145-156 (Pubitemid 351546456)
2. Badylak, S.F. Regenerative medicine and developmental biology: the role of the extracellular matrix. Anat Rec B New Anat. 2005; 287: 1, 36-41 (Pubitemid 41786968)
3. Brown, B., Lindberg, K., Reing, J. et al. Basement membrane component of biologic scaffolds derived from extracellular matrix. Tissue Eng. 2006; 12: 3, 519-526 (Pubitemid 43673457)
4. Chun, S.Y., Lim, G.J., Kwon, T.G. et al. Identification and characterization of bioactive factors in bladder submucosa matrix. Biomaterials. 2007; 28: 29, 4251-4256 (Pubitemid 47212395)
5. Brennan, E.P., Reing, J., Chew, D. et al. Antibacterial activity within degradation products of biological scaffolds composed of extracellular matrix. Tissue Eng. 2006; 12: 10, 2949-2955 (Pubitemid 46150658)
6. Sheehan, P., Jones, P., Caselli, A. et al. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care. 2003; 26: 6, 1879-1882 (Pubitemid 36929137)
7. Gentzkow, G.D., Iwasaki, S.D., Hershon, K.S. et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996; 19: 2, 350-354 (Pubitemid 26115458)
8. Warriner, R.A., Cardinal, M. Human fibroblastderived dermal substitute: results from a treatment investigational device exemption study in diabetic foot ulcers. Adv Skin Wound Care. 2011; 24: 7, 306-311
9. Frykberg, R.G., Tierney, E., Tallis, A. Decreased amputation through evidence based wound healing. J Diabetic Foot Complications. 2011; 3: 4, 62-67
10. Omar, A.A., Mavor, A.D., Jones, A.M., Homer-Vanniasinkam, S. Treatment of venous leg ulcers with dermagraft. Eur J Vasc Endovasc Surg. 2004; 27: 6, 666-672 (Pubitemid 38635012)
11. Marston, W.A., Hanft, J., Norwood, P., Pollak, R. The efficacy and safety of dermagraft in improving the healing of chronic diabetic foot ulcers. Diabetes Care. 2003; 26: 6, 1701-1705 (Pubitemid 36929107)
12. Buchberger, B., Follmann, M., Freyer, D. et al. The evidence for the use of growth factors and active skin substitutes for the treatment of non-infected diabetic foot ulcers: a health technology assessment. Exp Clin Endocrinol Diabetes. 2011; 119: 8, 472-479
13. Dinh, T.L., Veves, A. The efficacy of Apligraf in the treatment of diabetic foot ulcers. Plast Reconstr Surg. 2006; 117: 7S, 152-157
14. Edmonds, M. Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds. 2009; 8: 1, 11-18
15. Zaulyanov, L., Kirsner, R.S. A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers. Clin Interv Aging. 2007; 2: 1, 93-98
16. Edmonds, M.E., Blundell, M.P., Morris, M.E. et al. Improved survival of the diabetic foot: the role of a specialized foot clinic. Q J Med. 1986; 60: 232, 763-771. (Pubitemid 16008592)